A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Figure 3. Phosphorylated p70S6K best predicted ketamine response. The phosphorylated p70S6K marker had an AUC of 0.80 (confidence interval: 0.54-0.97) for predicting ketamine response. An optimal ...
Oncotarget published "High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC" which reported that the aim of this study was therefore to define ...
San Francisco–based Aeovian Pharmaceuticals has raised $37 million in series A financing to develop a small-molecule drug candidate that inhibits a protein complex called mammalian target of rapamycin ...
Littdd Medicines Ltd. has described mTOR complex 1 (mTORC1) and/or mTOR complex 2 (mTORC2) inhibitors reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, transplant ...
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. New soft tissue sarcoma (STS) transcriptomic clusters to ...
Panel A shows how insulin and insulin-like growth factor-1 (IGF-1) effect protein anabolism by signaling through their receptors (IR and IGF1R, respectively). This signaling results in the activation ...
The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...
Celcuity recently reported in the Journal of Clinical Oncology that its Phase 3 VIKTORIA-1 trial in PIK3CA wild-type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results